Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Roivant Sciences Ltd. ROIV

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$8.3M
▼ 71.6% YoY
$-299.8M
$-758.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. As of March 31, 2026, we and our subsidiaries had approximately 721 full-time employees, including 659 in the U.S. The development and commercialization of new drug products is highly competitive. We were registered as an exempted limited company in Bermuda in 2014, under the name Valor Biotechnology Ltd. In November 2014, we changed our name to Roivant Sciences Ltd.

Written from the business description in Roivant Sciences Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 20 May 2026. Every sentence was checked against that document before publication.

Growth

USD 8.3M
Revenue, FY2025 · full 6-year series below
Revenue $B Net income $B
FY2025 · Revenue 0.0 · Net income -0.3
2.0B4.0B-0.5B-1.0B
202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -6235.7%
5000%10000%-2000%-4000%-6000%
202020222025
ROE
FY2025 · ROE -6.5%
50%100%-20%-40%-60%
202020222025
Three returns, three denominators.

Each USD of equity lost 7 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -758.6
-300M-600M
202020222025
Net buybacks $B Dividends $B
FY2024 · Dividends · · Net buybacks 1.3
0.5B1.0B-0.1B-0.3B
202220232024

Total assetsUSD 5.7B
EquityUSD 4.5B
CashUSD 1.4B
Current ratio18.37×

Equity funds 79% of total assets.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
ROIV, 6-year financial record
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.10.0
Operating income $B−0.5−1.04.5−0.9−1.4−1.1
EBITDA $B−0.5−1.04.5−0.9−1.3◌
Income tax $B0.10.00.00.00.00.0
Net income $B−0.3−0.24.3−1.0−0.8−0.8
Free cash flow $B−0.8−0.8−0.8−0.9−0.7−0.6
EPS, diluted $−0.54−0.245.23−1.42−1.26−1.28
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %−6.5−3.2122.1−71.7−48.9−45.0
Shares out B0.720.700.810.760.690.65

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 24 reconciliationsAUDITED

Reconciled in 6 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code D0
Fiscal year endsMarch 31
Data on record since2020

Share this section

Download image